The rapid diagnostics developer expects full-year revenue of £11.3m for FY26 and confirmed second-half EBITDA profitability, with further growth flagged for FY27.

“These tax credits will support our expansion at University Research Park in Madison, including the creation of additional skilled roles,” said Chris Yates, President of Abingdon Health USA Inc.

The firm's CDMO work underpinned the UKCA-marked commercial launch and London Ambulance Service deployment of LVOne, a two-biomarker rapid blood test to identify likely large vessel occlusion strokes in under 10 minutes.

It will develop DPP3 InvoSelect, a lateral‑flow companion diagnostic, as legal manufacturer and CDMO for 4TEEN4 Pharmaceuticals' invobenitug antibody programme.